US scientific instruments manufacturer Bruker Corporation has acquired Canopy Biosciences, a life science company engaged in providing high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy, for an undisclosed price.
Bruker said that the acquisition boosts its offering in targeted multi-omics and fluorescence-based imaging techniques. The company claimed that its global presence, complementary technologies, and applications knowledge will help consolidate on the success of Canopy Biosciences so far.
Dr. Mark R. Munch – Bruker NANO Group President said: “We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker.
“Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”
Established in 2016, Canopy Biosciences has a portfolio of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. The Missouri-based company’s gene editing portfolio is said to provide easy-to-use CRISPR kits and full-service custom cell line engineering.
Dr. Edward Weinstein – CEO of Canopy Biosciences said: “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our powerful high-plex ChipCytometry platform, designed for accelerating basic immunology and clinical research, as well as biopharma drug development.”